Armata Pharmaceuticals, Inc.

What they do

Armata develops high-purity, pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections. It operates a research and development facility in Los Angeles, the McConnell Facility, which includes approximately 10,000 square feet of licensed cGMP drug manufacturing suites for producing, testing and releasing clinical trial material. The company has completed three Phase 2 clinical trials and advances two distinct candidates: inhaled AP-PA02 targeting Pseudomonas aeruginosa, and intravenous AP-SA02 targeting Staphylococcus aureus.

Revenue drivers

• AP-SA02 (S. aureus phage candidate) — Lead late-stage candidate for adjunct treatment of complicated S. aureus bacteremia caused by MSSA or MRSA; no product revenue is reported, so this represents future commercial potential rather than current sales.
• AP-PA02 (P. aeruginosa phage candidate) — Inhaled candidate for chronic pulmonary P. aeruginosa infection, including in cystic fibrosis; completed a Phase 1b/2a study with positive topline results announced in Q1 2023.
• Non-dilutive government funding — Armata reports receiving additional non-dilutive funding from its partners at the U.S. Department of War, which helps fund development of AP-SA02.
• In-house cGMP manufacturing — The company produces clinical trial material at its own Los Angeles cGMP suites; this is a development capability rather than a revenue line, though it supports commercialization goals and potential future DoW forward deployment.

Recent performance

For the second quarter ended June 30, 2026, Armata reported total assets of $90.0M, total liabilities of $321.1M, shareholder equity of negative $231.2M, and cash and equivalents of $24.0M. Annual net income was negative $173.8M in 2025, compared with negative $18.9M in 2024, while operating cash flow was negative $25.8M in 2025. Diluted EPS was negative $4.80 in 2025 versus negative $0.89 in 2024. The most recent quarterly revenue figure in the provided data is $31,000 for the quarter ended June 30, 2020.

Strategy

Armata's stated priority is finalizing activities required to initiate a pivotal Phase 3 superiority study of AP-SA02 in complicated S. aureus bacteremia in the second half of 2026. The company submitted the complete Phase 3 protocol to the FDA, responded to the Agency's End-of-Phase 2 meeting minutes, and continues to advance manufacturing. CMC work includes validating lot release assays for drug substance and drug product, completing four engineering runs of AP-SA02 at the in-house cGMP facility, and simplifying drug product for ease of bedside use and potential future U.S. Department of War forward deployment. The company also intends to support a future Biologics License Application for AP-SA02.

Risks

• Negative shareholder equity and heavy liabilities — As of June 30, 2026, total liabilities of $321.1M exceeded total assets of $90.0M, producing shareholder equity of negative $231.2M.
• Weak cash position relative to spending — Cash and equivalents were $24.0M at June 30, 2026, while 2025 operating cash flow was negative $25.8M, indicating a narrow funding runway.
• No meaningful product revenue — The company remains pre-commercial, with the only quarterly revenue figure provided at $31,000, and depends on financing and non-dilutive funding rather than sales.
• Clinical and regulatory execution risk — The pivotal Phase 3 superiority study of AP-SA02 is expected to begin in the second half of 2026, so timelines and eventual BLA submission depend on protocol, manufacturing and enrollment success.

Outlook

Management expects to initiate the pivotal Phase 3 superiority study of AP-SA02 in the second half of 2026, designed to support a future Biologics License Application. The company has received FDA Fast Track designation and agreement on an Agreed Initial Pediatric Study Plan for AP-SA02. Manufacturing of clinical trial material is the next planned step following four completed engineering runs.